Abivax SA ADR (NASDAQ:ABVX) shares rose 2.6% in premarket trading on Thursday after the clinical-stage biotechnology company announced that 22 scientific abstracts have been accepted for presentation at the European Crohn’s and Colitis Organization’s (ECCO) 21st Annual Congress, scheduled for February 2026.
The accepted presentations will highlight new and existing data on obefazimod, Abivax’s investigational therapy for inflammatory bowel disease (IBD). The company said the abstracts include one oral presentation, five digital oral presentations and 16 poster sessions, underscoring the growing breadth of clinical and preclinical evidence supporting the drug candidate.
A key highlight will be an oral presentation on February 21, 2026, which is set to disclose new preclinical data demonstrating obefazimod’s anti-fibrotic effects in IBD models. This development targets a significant unmet need in Crohn’s disease, where intestinal fibrosis frequently leads to serious complications and the need for surgical intervention.
The accepted abstracts also include subgroup analyses from the Phase 3 ABTECT Induction Trials in ulcerative colitis. These analyses show obefazimod’s clinical activity across different patient populations, its ability to reduce pro-inflammatory cytokines, and evidence of early symptom relief.
“We are highly enthusiastic about the strong presence of obefazimod data at the 21st ECCO Congress, highlighting the impactful and robust data we have generated in inflammatory bowel disease,” said Marc de Garidel, Chief Executive Officer of Abivax.
Abivax’s Chief Medical Officer, Fabio Cataldi, highlighted the importance of the anti-fibrotic findings, noting that intestinal fibrosis is “a major complication of Crohn’s disease that is not fully addressed by current therapies.”
Obefazimod is designed to leverage the body’s natural regulatory pathways to help stabilize immune responses in patients suffering from chronic inflammatory conditions.